Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H21ClN4OS |
Molecular Weight | 412.936 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC2=C(CC(=O)N2)C=C1CCN3CCN(CC3)C4=NSC5=C4C=CC=C5
InChI
InChIKey=MVWVFYHBGMAFLY-UHFFFAOYSA-N
InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)
Molecular Formula | C21H21ClN4OS |
Molecular Weight | 412.936 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://effectivehealthcare.ahrq.gov/ehc/products/150/786/CER43_Off-LabelAntipsychotics_execsumm_20110928.pdf
Curator's Comment: description was created based on several sources, including
https://effectivehealthcare.ahrq.gov/ehc/products/150/786/CER43_Off-LabelAntipsychotics_execsumm_20110928.pdf
Ziprasidone is atypical antipsychotic, approved by the U.S. Food and Drug Administration for the treatment of schizophrenia, and acute mania and mixed states associated with bipolar disorder. Intramuscilar injections of Ziprasidone are indicated for rapid control of the agitation in schizophrenic patients. Ziprasidone is used off-label for treatment of major depressive disorder, anxiety, obsessive compulsive disorder, borderline personality disorder. Ziprasidone functions as an antagonist at the D2, 5HT2A, and 5HT1D receptors, and as an agonist at the 5HT1A receptor.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL217 |
4.8 nM [Ki] | ||
Target ID: CHEMBL3737 |
3.4 nM [Ki] | ||
Target ID: CHEMBL224 |
0.4 nM [Ki] | ||
Target ID: CHEMBL1983 |
2.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | GEODON Approved UseZiprasidone hydrochloride capsule is an atypical antipsychotic. In choosing among treatments, prescribers should be aware of the capacity of ziprasidone hydrochloride capsule to prolong the QT interval and may consider the use of other drugs first. Launch Date9.8133121E11 |
|||
Primary | GEODON Approved UseZiprasidone hydrochloride capsule is an atypical antipsychotic. In choosing among treatments, prescribers should be aware of the capacity of ziprasidone hydrochloride capsule to prolong the QT interval and may consider the use of other drugs first. Ziprasidone intramuscular is indicated for the treatment of acute agitation in schizophrenic patients for whom treatment with ziprasidone is appropriate and who need intramuscular antipsychotic medication for rapid control of the agitation. “Psychomotor agitation” is defined in DSM-IV as “excessive motor activity associated with a feeling of inner tension.” Launch Date9.8133121E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
51 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16721322 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZIPRASIDONE serum | Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
457 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16721322 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZIPRASIDONE serum | Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16721322 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZIPRASIDONE serum | Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
ZIPRASIDONE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
4480 mg single, oral Overdose Dose: 4480 mg Route: oral Route: single Dose: 4480 mg Co-administed with:: Clomethiazole(192 mg) Sources: |
unhealthy, 22 years n = 1 Health Status: unhealthy Condition: Paranoid Schizophrenia Age Group: 22 years Sex: M Population Size: 1 Sources: |
Disc. AE: Sedation, Hypotension... AEs leading to discontinuation/dose reduction: Sedation (1 patient) Sources: Hypotension (1 patient) |
20 mg single, oral Overdose |
healthy, 30 month n = 1 Health Status: healthy Age Group: 30 month Sex: F Population Size: 1 Sources: |
Disc. AE: Respiratory depression... AEs leading to discontinuation/dose reduction: Respiratory depression (1 patient) Sources: |
780 mg single, oral Overdose |
unhealthy, 31 years n = 1 Health Status: unhealthy Condition: Mixed personality disorder Age Group: 31 years Sex: M Population Size: 1 Sources: |
Disc. AE: Drowsiness... AEs leading to discontinuation/dose reduction: Drowsiness (1 patient) Sources: |
1120 mg single, oral Overdose Dose: 1120 mg Route: oral Route: single Dose: 1120 mg Sources: |
unhealthy, 35 years n = 1 Health Status: unhealthy Condition: Schizophrenia Age Group: 35 years Sex: M Population Size: 1 Sources: |
|
4400 mg single, oral Overdose Dose: 4400 mg Route: oral Route: single Dose: 4400 mg Co-administed with:: Clomethiazole(768 mg) Sources: flunitrazepam(4 mg) |
unhealthy, 57 years n = 1 Health Status: unhealthy Condition: Manic-depressive disorder Age Group: 57 years Sex: F Population Size: 1 Sources: |
Disc. AE: Drowsiness, Tremor... AEs leading to discontinuation/dose reduction: Drowsiness (1 patient) Sources: Tremor (1 patient) Anxiety (1 patient) |
20 mg 2 times / day steady, intramuscular Studied dose Dose: 20 mg, 2 times / day Route: intramuscular Route: steady Dose: 20 mg, 2 times / day Sources: |
unhealthy, 60 – 81 years n = 21 Health Status: unhealthy Condition: Schizophrenia Age Group: 60 – 81 years Sex: M+F Population Size: 21 Sources: |
Other AEs: Blurred vision, Sedation... Other AEs: Blurred vision (1 patient) Sources: Sedation (1 patient) |
40 mg 1 times / day steady, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, 7 – 17 years n = 28 Health Status: unhealthy Condition: Tourette's syndrome Age Group: 7 – 17 years Sex: M+F Population Size: 28 Sources: |
Other AEs: Somnolence, Akathisia... Other AEs: Somnolence (1 patient) Sources: Akathisia (1 patient) |
20 mg single, oral |
unhealthy, 7-16 years n = 24 Health Status: unhealthy Condition: Tourette's disorder or chronic tic disorder Age Group: 7-16 years Sex: M+F Population Size: 24 Sources: |
Other AEs: Somnolence, Syncope hypotensive... Other AEs: Somnolence (16 patients) Sources: Syncope hypotensive (2 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypotension | 1 patient Disc. AE |
4480 mg single, oral Overdose Dose: 4480 mg Route: oral Route: single Dose: 4480 mg Co-administed with:: Clomethiazole(192 mg) Sources: |
unhealthy, 22 years n = 1 Health Status: unhealthy Condition: Paranoid Schizophrenia Age Group: 22 years Sex: M Population Size: 1 Sources: |
Sedation | 1 patient Disc. AE |
4480 mg single, oral Overdose Dose: 4480 mg Route: oral Route: single Dose: 4480 mg Co-administed with:: Clomethiazole(192 mg) Sources: |
unhealthy, 22 years n = 1 Health Status: unhealthy Condition: Paranoid Schizophrenia Age Group: 22 years Sex: M Population Size: 1 Sources: |
Respiratory depression | 1 patient Disc. AE |
20 mg single, oral Overdose |
healthy, 30 month n = 1 Health Status: healthy Age Group: 30 month Sex: F Population Size: 1 Sources: |
Drowsiness | 1 patient Disc. AE |
780 mg single, oral Overdose |
unhealthy, 31 years n = 1 Health Status: unhealthy Condition: Mixed personality disorder Age Group: 31 years Sex: M Population Size: 1 Sources: |
Anxiety | 1 patient Disc. AE |
4400 mg single, oral Overdose Dose: 4400 mg Route: oral Route: single Dose: 4400 mg Co-administed with:: Clomethiazole(768 mg) Sources: flunitrazepam(4 mg) |
unhealthy, 57 years n = 1 Health Status: unhealthy Condition: Manic-depressive disorder Age Group: 57 years Sex: F Population Size: 1 Sources: |
Drowsiness | 1 patient Disc. AE |
4400 mg single, oral Overdose Dose: 4400 mg Route: oral Route: single Dose: 4400 mg Co-administed with:: Clomethiazole(768 mg) Sources: flunitrazepam(4 mg) |
unhealthy, 57 years n = 1 Health Status: unhealthy Condition: Manic-depressive disorder Age Group: 57 years Sex: F Population Size: 1 Sources: |
Tremor | 1 patient Disc. AE |
4400 mg single, oral Overdose Dose: 4400 mg Route: oral Route: single Dose: 4400 mg Co-administed with:: Clomethiazole(768 mg) Sources: flunitrazepam(4 mg) |
unhealthy, 57 years n = 1 Health Status: unhealthy Condition: Manic-depressive disorder Age Group: 57 years Sex: F Population Size: 1 Sources: |
Blurred vision | 1 patient | 20 mg 2 times / day steady, intramuscular Studied dose Dose: 20 mg, 2 times / day Route: intramuscular Route: steady Dose: 20 mg, 2 times / day Sources: |
unhealthy, 60 – 81 years n = 21 Health Status: unhealthy Condition: Schizophrenia Age Group: 60 – 81 years Sex: M+F Population Size: 21 Sources: |
Sedation | 1 patient | 20 mg 2 times / day steady, intramuscular Studied dose Dose: 20 mg, 2 times / day Route: intramuscular Route: steady Dose: 20 mg, 2 times / day Sources: |
unhealthy, 60 – 81 years n = 21 Health Status: unhealthy Condition: Schizophrenia Age Group: 60 – 81 years Sex: M+F Population Size: 21 Sources: |
Akathisia | 1 patient | 40 mg 1 times / day steady, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, 7 – 17 years n = 28 Health Status: unhealthy Condition: Tourette's syndrome Age Group: 7 – 17 years Sex: M+F Population Size: 28 Sources: |
Somnolence | 1 patient | 40 mg 1 times / day steady, oral Studied dose Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, 7 – 17 years n = 28 Health Status: unhealthy Condition: Tourette's syndrome Age Group: 7 – 17 years Sex: M+F Population Size: 28 Sources: |
Somnolence | 16 patients | 20 mg single, oral |
unhealthy, 7-16 years n = 24 Health Status: unhealthy Condition: Tourette's disorder or chronic tic disorder Age Group: 7-16 years Sex: M+F Population Size: 24 Sources: |
Syncope hypotensive | 2 patients | 20 mg single, oral |
unhealthy, 7-16 years n = 24 Health Status: unhealthy Condition: Tourette's disorder or chronic tic disorder Age Group: 7-16 years Sex: M+F Population Size: 24 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-825_Geodan_pharmr_P2.pdf#page=16 Page: 16.0 |
no [IC50 >100 uM] | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-825_Geodan_pharmr_P2.pdf#page=16 Page: 16.0 |
no [IC50 >100 uM] | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-825_Geodan_pharmr_P2.pdf#page=16 Page: 16.0 |
no [IC50 >100 uM] | |||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no | ||||
Page: 16, (ClinPharm) 16, (ClinPharm4) 58-60 |
yes [IC50 5.8 uM] | no (co-administration study) Comment: Estimated Cfree,plasma = 0.29-0.73 nM (80mg BID); Coadministration of Ziprasidone had no effect on the urinary Dextromethorphan/Dextrophan ratio. Page: 16, (ClinPharm) 16, (ClinPharm4) 58-60 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-825_Geodan_pharmr_P2.pdf#page=16 Page: 16.0 |
yes [Ki 64 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-825_Geodan_biopharmr_P3.pdf#page=68 Page: (ClinPharm3) 68 |
likely | |||
Page: 15-16, (ClinPhar) 15-16, (ClinPharm3) 65-66, (ClinPharm4) 35-38, 64-66 |
major | yes (co-administration study) Comment: Ketoconazole inhibited formation of Ziprasidone sulfoxide by 77% in vitro.; Coadministration of Ketoconazoke (strong CYP3A4 inhibitor) increased Ziprasidone AUC and Cmax by about 30%. Coadministration of Carbamazepine (strong CYP3A4 inducer) decreased Ziprasidone AUC by 36% and Cmax by 27%. Page: 15-16, (ClinPhar) 15-16, (ClinPharm3) 65-66, (ClinPharm4) 35-38, 64-66 |
||
Page: 15-16, (ClinPharm3) 65-66, 68 |
minor | |||
Sources: https://go.drugbank.com/drugs/DB00246 |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Hyperglycemia and antipsychotic medications. | 2001 |
|
Pharmacological options for the treatment of Tourette's disorder. | 2001 |
|
Focus on ziprasidone. | 2001 |
|
Review of atypical antipsychotics and weight gain. | 2001 |
|
Tourette syndrome: clinical characteristics and current management strategies. | 2001 |
|
Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations. | 2001 Autumn |
|
Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence. | 2001 Jan |
|
Use of atypical antipsychotics in mood disorders. | 2001 Jul |
|
Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone. | 2001 Jul-Aug |
|
Ziprasidone: a new atypical antipsychotic. | 2001 Jun |
|
Ziprasidone approved. | 2001 Jun |
|
Ziprasidone, a new atypical antipsychotic drug. | 2001 Jun |
|
Ziprasidone (Geodon) for schizophrenia. | 2001 Jun 11 |
|
The apparent effects of ziprasidone on plasma lipids and glucose. | 2001 May |
|
New schizophrenia drug. | 2001 May-Jun |
|
Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. | 2001 Nov |
|
Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. | 2001 Nov 2 |
|
Ziprasidone: profile on safety. | 2001 Oct |
|
Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation. | 2001 Oct 5 |
|
Psychopharmacology news. | 2001 Summer |
|
Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. | 2002 |
|
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. | 2002 |
|
Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. | 2002 |
|
Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. | 2002 |
|
Effects of newer antipsychotics on extrapyramidal function. | 2002 |
|
Case series: use of ziprasidone for maladaptive symptoms in youths with autism. | 2002 Aug |
|
Tardive dyskinesia and ziprasidone. | 2002 Aug |
|
Atypical antipsychotics: mechanism of action. | 2002 Feb |
|
New drugs 2002, part 1. | 2002 Jan |
|
Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. | 2002 Jan |
|
The value of atypical antipsychotics in the treatment of schizophrenia. | 2002 Jul |
|
Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors. | 2002 Jul |
|
The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia. | 2002 Jul 3 |
|
A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. | 2002 Jun |
|
Prolongation of QTc interval and antipsychotics. | 2002 Jun |
|
Overdose of ziprasidone. | 2002 Jun |
|
5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. | 2002 Jun 7 |
|
Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. | 2002 Mar |
|
Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. | 2002 Mar |
|
Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. | 2002 May |
|
[Exercising caution in choice of psychotropic drugs. Avoid drug-induced weight gain]. | 2002 May 6 |
|
[Psychopharmacological treatment of bipolar disease]. | 2002 May 6 |
|
Antipsychotics: impact on prolactin levels. | 2002 Oct |
|
Ziprasidone alternative for olanzapine-induced hyperglycemia. | 2002 Sep |
|
Comprehensive understanding of schizophrenia and its treatment. | 2002 Sep 1 |
|
Clinical issues associated with maintenance treatment of patients with schizophrenia. | 2002 Sep 1 |
|
Cataract occurrence with antipsychotic drugs. | 2002 Sep-Oct |
|
Antipsychotic-induced hyperprolactinemia and sexual dysfunction. | 2002 Winter |
|
Ziprasidone-associated galactorrhea in a female teenager. | 2003 Jan |
Sample Use Guides
For treatment of schizophrenia, GEODON capsules should be administered at an initial daily dose of 20 mg BID with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to 80 mg BID. Systematic evaluation of ziprasidone has shown that its efficacy in schizophrenia is maintained for periods of up to 52 weeks at a dose of 20 to 80 mg BID. For treatment of bipolar mania, oral ziprasidone should be administered at an initial daily dose of 40 mg BID with food. The dose should then be increased to 60 mg or 80 mg BID on the second day of treatment and subsequently adjusted on the basis of toleration and efficacy within the range 40-80 mg BID. The recommended dose for intramuscular administration is 10 to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8568801
Standard receptor-binding methods were used to label dopamine D2 receptors using [3H]spiperone. Briefly, rats were sacrificed by decapitation and the brains rapidly removed. The corpus striatum was dissected and homogenized in 20 vol at 50 mM Tris HCl (pH 7.2) buffer using a Brinkman Polytron homogenizer (setting 7 for 15 s). The homogenate was centrifuged for 10 min at 40000g. The pellet was resuspended in fresh ice-cold 50 mM Tris (pH 7.2) buffer with the Polytron homogenizer and recentrifuged. The final pellet was resuspended in 50 mM Tris HCl buffer (pH 7.2) containing 1 mM MgCl2 and 100 mM NaCl. Assays were initiated by the addition of tissue to tubes containing [3H]spiperone (0.2 nM) and drug or buffer in a final volume of 1 mL. Blocking agents (500 nM cinanserin and 1 mM prazosin) were present to prevent [3H]spiperone from labeling 5-HT2 and R1 noradrenergic receptors. Nonspecific binding was defined as the radioligand bound in the presence of 10 uM (+)-butaclamol. After a 15 min incubation at 37 °C, tissue samples were filtered onto Whatman GF/B glass fiber filters using a Brandel harvester and rinsed two times with 5 mL of ice-cold 50 mM Tris HCl (pH 7.4) buffer. Filters were soaked in 10 mL of Ready-Safe (Beckman Instruments), and the radioactivity was quantified using liquid scintillation counting. Ziprasidone binds to D2 receptors with pKi of 8.32 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 23:13:20 UTC 2023
by
admin
on
Thu Jul 06 23:13:20 UTC 2023
|
Record UNII |
6UKA5VEJ6X
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
NBK548663
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
||
|
WHO-VATC |
QN05AE04
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
||
|
NDF-RT |
N0000175430
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
||
|
NCI_THESAURUS |
C29710
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
||
|
WHO-ATC |
N05AE04
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
10119
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY | |||
|
60854
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY | |||
|
59
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY | |||
|
100000078790
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY | |||
|
115698
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY | RxNorm | ||
|
6UKA5VEJ6X
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY | |||
|
CHEMBL708
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY | |||
|
DB00246
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY | |||
|
ZIPRASIDONE
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY | |||
|
C092292
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY | |||
|
SUB00168MIG
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY | |||
|
Ziprasidone
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY | |||
|
7745
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY | |||
|
7155
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY | |||
|
2865
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY | |||
|
6UKA5VEJ6X
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY | |||
|
DTXSID4023753
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY | |||
|
C47788
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY | |||
|
M11641
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY | Merck Index | ||
|
146939-27-7
Created by
admin on Thu Jul 06 23:13:23 UTC 2023 , Edited by admin on Thu Jul 06 23:13:23 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> AGONIST |
SHORT-ACTING
|
||
|
DEGRADENT -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
MAJOR
|
||
|
METABOLITE -> PARENT |
MAJOR
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
MAJOR
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||